Patents by Inventor Michael Kragh

Michael Kragh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180327500
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Application
    Filed: September 15, 2015
    Publication date: November 15, 2018
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • Patent number: 10058610
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 28, 2018
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20170165365
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: November 14, 2016
    Publication date: June 15, 2017
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20170152322
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Application
    Filed: November 28, 2016
    Publication date: June 1, 2017
    Inventors: Mikkel Wandahl Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • Patent number: 9527913
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 27, 2016
    Assignee: SYMPHOGEN A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Publication number: 20160089435
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Application
    Filed: September 23, 2015
    Publication date: March 31, 2016
    Inventors: Mikkel Wandahl Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • Patent number: 9155802
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: October 13, 2015
    Assignee: SYMPHOGEN A/S
    Inventors: Mikkel W. Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • Publication number: 20150086478
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Patent number: 8663640
    Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: March 4, 2014
    Assignee: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Michael Kragh, Adam S. Hey, Helle Jacobsen
  • Patent number: 8581021
    Abstract: The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: November 12, 2013
    Assignee: Aarhus Universitet
    Inventors: Jacob Giehm Mikkelsen, Brian Moldt, Anders Lade Nielsen, Lars Axel Bolund, Peter Michael Kragh, Jannik Ejnar Jakobsen, Arne Lund Jørgensen
  • Patent number: 8546643
    Abstract: The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof, LDL gene or part thereof, LDL receptor gene, or transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of atherosclerosis; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from atherosclerosis are disclosed.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: October 1, 2013
    Assignee: Aarhus Universitet
    Inventors: Jacob Fog Bentzon, Charlotte Brandt Sørensen, Peter Michael Kragh, Jacob Giehm Mikkelsen, Erling Falk, Lars Axel Bolund, Thomas Juhl Corydon
  • Patent number: 8513486
    Abstract: The present invention discloses methods for cell nuclear transfer that comprise for example modification of zona pellucida of an oocyte, and/or sectioning of oocytes into several parts. The present invention also discloses methods for producing a genetically modified non-human mammal. Genetically modified non-human mammals obtainable by the disclosed methods are also within the scope of the present invention. Disclosed are also methods for cryopreservation of cells.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: August 20, 2013
    Assignee: Aarhus Universitet
    Inventors: Yutao Du, Lars Axel Bolund, Gabor Vajta, Peter Michael Kragh
  • Publication number: 20130150465
    Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.
    Type: Application
    Filed: August 22, 2012
    Publication date: June 13, 2013
    Applicant: Aarhus Universitet
    Inventors: Peter Michael Kragh, Lars Axel Bolund, Charlotte Brandt Sørensen, Thomas Juhl Corydon, Niels Gregersen, Peter Bross
  • Publication number: 20120107234
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 3, 2012
    Inventors: Mikkel W. PEDERSEN, Ida K. CHRISTENSEN, Johan LANTTO, Helle JACOBSEN, Michael KRAGH
  • Publication number: 20110229463
    Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumours following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumours. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
    Type: Application
    Filed: August 27, 2009
    Publication date: September 22, 2011
    Applicant: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Michael Kragh, Adam S. Hey, Helle Jacobsen
  • Publication number: 20100154069
    Abstract: The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, foetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
    Type: Application
    Filed: March 7, 2008
    Publication date: June 17, 2010
    Applicant: AARHUS UNIVERSITET
    Inventors: Jacob Giehm Mikkelsen, Brian Moldt, Anders Lade Nielsen, Lars Axel Bolund, Peter Michael Kragh, Jannik Ejnar Jakobsen, Arne Lund Jørgensen
  • Publication number: 20100138939
    Abstract: The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof and/or LDL gene or part thereof, and/or LDL receptor gene, and/or transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of atherosclerosis; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from atherosclerosis are disclosed.
    Type: Application
    Filed: March 6, 2008
    Publication date: June 3, 2010
    Applicant: AARHUS UNIVERSITET
    Inventors: Jacob Fog Bentzon, Charlotte Brandt Sørensen, Peter Michael Kragh, Jacob Giehm Mikkelsen, Erling Falk, Lars Axel Bolund, Thomas Juhl Corydon
  • Publication number: 20100122356
    Abstract: The present invention relates to a genetically modified pig as a model for studying psoriasis. The modified pig model displays one or more phenotypes associated with psoriasis. Disclosed is also a modified pig comprising a mutation in the endogenous ILK-I Ra, JunB/cJun, CD18, IKK2, and/or LIG1 gene, and/or a human, porcine and/or murine PPARs, PPAR-?, l?B-?, STAT3c, Integrin beta 1, Integrin alpha 2, MEK1, Amphiregulin, BMP-6, VEGF, JunB?ec-Jun?ep, IL-I a, TGF.beta 1, CD18 hypo, Cre/lkk2FL/FL, Dsg1, SCCE, TGF-a, TNF-a, IL-20, IFN-g, LIG1 KO, KGF, IL-6, PAFR1 Cre/lkk2FL/FL, IL1 R, Dsg3, IFN-gamma, p40, ILI Ra, IKK2, JunB/c-Jun, and/or LIG1 gene, transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of psoriasis, for screening the efficacy of a pharmaceutical composition, and a method for treatment of human being suffering from psoriasis are disclosed.
    Type: Application
    Filed: March 7, 2008
    Publication date: May 13, 2010
    Applicants: AARHUS UNIVERSITET, LEO PHARMA A/S, SYDDANSK UNIVERSITET
    Inventors: Peter Michael Kragh, Lars Axel Bolund, Karsten Kristiansen, Charlotte Brandt Sørensen, Jacob Giehm Mikkelsen, Nicklas Heine Staunstrup, Thomas Kongstad Petersen, Lars Svensson
  • Publication number: 20100115636
    Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA 2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.
    Type: Application
    Filed: March 6, 2008
    Publication date: May 6, 2010
    Applicant: AARHUS UNIVERSITET
    Inventors: Peter Michael Kragh, Lars Axel Bolund, Charlotte Brandt Sorensen, Thomas Juhl Corydon, Niels Gregersen, Peter Bross
  • Publication number: 20090119787
    Abstract: The present invention discloses methods for cell nuclear transfer that comprise for example modification of zona pellucida of an oocyte, and/or sectioning of oocytes into several parts. The present invention also discloses methods for producing a genetically modified non-human mammal. Genetically modified non-human mammals obtainable by the disclosed methods are also within the scope of the present invention. Disclosed are also methods for cryopreservation of cells.
    Type: Application
    Filed: September 8, 2006
    Publication date: May 7, 2009
    Applicant: Aarhus Universitet
    Inventors: Yutao Du, Lars Axel Bolund, Gabor Vajta, Peter Michael Kragh